Stock 300685 AMOY DIAGNOSTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Amoy Diagnostics Co., Ltd.

Equities

300685

CNE1000034D3

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
21.88 CNY -.--% Intraday chart for Amoy Diagnostics Co., Ltd. +1.53% -0.45%
04-22 Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-15 Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,836 17,356 16,742 10,531 8,675 8,635 - -
Enterprise Value (EV) 1 9,836 16,995 16,342 10,089 8,176 7,913 7,545 7,337
P/E ratio 71.1 x 96.6 x 69.9 x 39.5 x 34.3 x 27.6 x 22.6 x 18.4 x
Yield - 0.32% 0.3% 0.53% 0.68% 0.66% 0.81% 0.95%
Capitalization / Revenue 17 x 23.8 x 18.3 x 12.5 x 8.31 x 6.75 x 5.54 x 4.62 x
EV / Revenue 17 x 23.3 x 17.8 x 12 x 7.83 x 6.18 x 4.84 x 3.92 x
EV / EBITDA 52.3 x 73.7 x 56.3 x 30 x 22.7 x 20.6 x 16.9 x 13.4 x
EV / FCF - 104 x 169 x - 30.7 x 68.8 x 27 x 20.2 x
FCF Yield - 0.96% 0.59% - 3.26% 1.45% 3.71% 4.95%
Price to Book 10.9 x 15.4 x 12.3 x 7.02 x 5.15 x 4.44 x 3.82 x 3.23 x
Nbr of stocks (in thousands) 397,456 399,254 399,101 398,157 394,659 394,659 - -
Reference price 2 24.75 43.47 41.95 26.45 21.98 21.88 21.88 21.88
Announcement Date 26/02/20 18/02/21 28/02/22 14/04/23 05/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 578.4 728.4 917 842.2 1,044 1,280 1,560 1,870
EBITDA 1 187.9 230.5 290.4 336.4 360.4 383.7 445.7 548
EBIT 1 162.5 202.1 253.2 287.7 295.1 357.8 421.1 515.7
Operating Margin 28.09% 27.75% 27.61% 34.16% 28.28% 27.96% 27% 27.58%
Earnings before Tax (EBT) 1 161.3 200.7 252 286.1 288.7 353.1 430.8 531.9
Net income 1 135.5 180.3 239.6 263.7 256.3 315.4 385.7 474.3
Net margin 23.42% 24.76% 26.12% 31.32% 24.56% 24.65% 24.73% 25.36%
EPS 2 0.3482 0.4500 0.6000 0.6700 0.6400 0.7922 0.9693 1.190
Free Cash Flow 1 - 162.9 96.91 - 266.4 115 279.6 363.2
FCF margin - 22.37% 10.57% - 25.52% 8.99% 17.93% 19.42%
FCF Conversion (EBITDA) - 70.69% 33.37% - 73.9% 29.97% 62.74% 66.28%
FCF Conversion (Net income) - 90.34% 40.45% - 103.94% 36.46% 72.51% 76.59%
Dividend per Share 2 - 0.1389 0.1278 0.1400 0.1500 0.1448 0.1771 0.2085
Announcement Date 26/02/20 18/02/21 28/02/22 14/04/23 05/02/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 271.3 206 186.5 206.8 242.9 195.2 263.5 248.9 336 233.3 326 324.8 397.6 287.4 -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 56.23 59.06 46.86 150.3 31.43 65.49 79.47 51.65 98.53 74.95 90.07 70.61 90.2 - -
Operating Margin 20.72% 28.66% 25.13% 72.71% 12.94% 33.56% 30.15% 20.75% 29.33% 32.13% 27.63% 21.74% 22.69% - -
Earnings before Tax (EBT) 1 55.79 - - - - - - 49.96 95.19 73.57 84.74 84.74 103.6 - -
Net income 1 63.02 - - - - - - 46.97 82.52 64.2 80.38 80.38 98.25 - -
Net margin 23.23% - - - - - - 18.87% 24.56% 27.52% 24.66% 24.75% 24.71% - -
EPS 2 0.1611 0.1333 0.0900 0.3400 0.1100 0.1400 0.1800 0.1200 0.2000 0.1600 0.2108 0.1758 0.2432 0.1600 -
Dividend per Share 2 0.1278 - - - 0.1400 - - - - - - - 0.1587 - -
Announcement Date 28/02/22 20/04/22 29/07/22 24/10/22 14/04/23 21/04/23 31/07/23 23/10/23 05/02/24 22/04/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - 362 400 443 498 722 1,090 1,298
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - 163 96.9 - 266 115 280 363
ROE (net income / shareholders' equity) 16.3% 17.8% 19.2% 18.4% 15.7% 16.3% 17.3% 18%
ROA (Net income/ Total Assets) - 15.4% 16.5% - - 14.4% 15.1% 15.5%
Assets 1 - 1,170 1,455 - - 2,195 2,561 3,066
Book Value Per Share 2 2.270 2.830 3.420 3.770 4.270 4.930 5.730 6.770
Cash Flow per Share 2 0.3800 0.5500 0.4200 0.3700 0.7500 0.6100 0.7500 1.010
Capex 1 - 57.8 71.2 26.4 32.4 57.8 52.8 57.9
Capex / Sales - 7.93% 7.77% 3.13% 3.1% 4.52% 3.38% 3.09%
Announcement Date 26/02/20 18/02/21 28/02/22 14/04/23 05/02/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Amoy Diagnostics Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.88 CNY
Average target price
28.6 CNY
Spread / Average Target
+30.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
AMOY DIAGNOSTICS CO., LTD. Stock Amoy Diagnostics Co., Ltd.
-0.45% 1.19B
BIOMÉRIEUX Stock bioMérieux
-1.89% 12.56B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.68B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-1.31% 5.29B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+21.82% 5.18B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.57B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.89% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.6B
VITROLIFE AB Stock Vitrolife AB
-10.02% 2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.29% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 300685 Stock
  4. Financials Amoy Diagnostics Co., Ltd.